CAS 781613-23-8: N-(3,4-Dichloro-2-fluorophenyl)-6-methoxy-7-{[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy}-4-quinazolinamine
Formula:C24H25Cl2FN4O2
InChI:InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13?,14-,15+
- Synonyms:
- Xl647
- 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aa,5a,6aa)-octahydro- 2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-
- Xl 647

XL647
CAS:781613-23-8
Formula:
C24H25Cl2FN4O2
Purity:
99%
Color and Shape:
Solid
Molecular weight:
491.38530319999984
Ref: IN-DA00G3QJ
1mg | 196.00 € | ||
5mg | 196.00 € | ||
10mg | 331.00 € | ||
25mg | 621.00 € | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Wednesday 16 Apr 2025

N-(3,4-Dichloro-2-Fluorophenyl)-6-Methoxy-7-(((3aR,5R,6aS)-2-Methyloctahydrocyclopenta[c]Pyrrol-5-Yl)Methoxy)Quinazolin-4-Amine
CAS:781613-23-8
Purity:
98%
Molecular weight:
491.39g/mol
Ref: 54-PC108514
100mg | 1,781.00 € | ||
250mg | 3,027.00 € |
Estimated delivery in United States, on Thursday 17 Apr 2025

Ref: 54-BUP08766
25mg | 1,099.00 € | ||
50mg | 1,390.00 € | ||
100mg | 1,711.00 € | ||
200mg | 2,888.00 € |
Estimated delivery in United States, on Thursday 17 Apr 2025

Tesevatinib
CAS:781613-23-8
Tesevatinib (XL-647) is an oral, multi-targeted tyrosine kinase inhibitor.Cost-effective and quality-assured.
Formula:
C24H25Cl2FN4O2
Purity:
97.89% - 97.89%
Color and Shape:
Solid
Molecular weight:
491.39
Ref: TM-TQ0166
1mg | 107.00 € | ||
2mg | 156.00 € | ||
5mg | 236.00 € | ||
10mg | 457.00 € | ||
25mg | 750.00 € | ||
50mg | 1,026.00 € | ||
1mL*10mM (DMSO) | 255.00 € |
Estimated delivery in United States, on Wednesday 23 Apr 2025

XL 647
CAS:781613-23-8
Inhibitor of EGFR, HER2 and VEGFR2 tyrosine kinases
Formula:
C24H25Cl2FN4O2
Purity:
Min. 95%
Molecular weight:
491.38 g/mol
Ref: 3D-FX103992
50mg | 1,728.00 € | ||
100mg | 2,604.00 € | ||
250mg | 4,953.00 € |
Estimated delivery in United States, on Wednesday 28 May 2025